Books in Neoplastic cancer pharmacology

11-19 of 19 results in All results

Personalized Cancer Chemotherapy

• 1st Edition
• December 5, 2014
• Da Yong Lu
• English
• Hardback 978-0-08-100346-6

  9 7 8 - 0 - 0 8 - 1 0 0 3 4 6 - 6
• eBook 978-0-08-100347-3

  9 7 8 - 0 - 0 8 - 1 0 0 3 4 7 - 3

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.

Biochemical and Molecular Aspects of Selected Cancers

• 1st Edition
• May 10, 2014
• Thomas G. Pretlow + 1 more
• English
• eBook 978-1-4832-8205-3

  9 7 8 - 1 - 4 8 3 2 - 8 2 0 5 - 3

Biochemical and Molecular Aspects of Selected Cancers, Volume I provides an overview of important topics and prototypes in cancer research. The book consists of papers provided by outstanding investigators in diverse disciplines in different areas of cancer research. This volume focuses on topics relevant to cancers in humans. It covers such topics as tumor-suppressor genes and human neoplasia; protein kinase C in neoplastic cells; and extracellular matrix interactions with tumor-progressing cells: tumor versus cell type-specific mechanisms. Structural and functional characteristics of human melanoma; steroid hormones and hormone receptors in neoplastic diseases; and patterns and significance of genetic changes in neuroblastomas are expounded as well. Oncologists, biochemists, cytologists, and other researchers in allied fields will find the book invaluable.

International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November 13 to 15, 1969

• 1st Edition
• October 22, 2013
• G. Raspé + 1 more
• English
• eBook 978-1-4831-8711-2

  9 7 8 - 1 - 4 8 3 1 - 8 7 1 1 - 2

International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November 13 to 15, 1969 presents a resolution to the doubts and uncertainty in the treatment of carcinoma and formulate a new policy for handling. It discusses the basis of hormonal treatment of prostatic cancer. The focus of study is the pharmacological aspects of prostate cancer treatment. Some of the topics covered in the book are the metabolism of testosterone in the prostate, the use of stilbestrol diphosphate in treating prostate cancer, the pathology of prostate cancer, and the cardiovascular complications of the disease. The subjects on orchiectomy and adrenalectomy are covered. The modern radiotherapy is discussed. The text identifies the use of radioactive isotopes. An analysis of the irradiation of the hypophysis is presented. A chapter of the volume is devoted to the cytotoxic agents in prostate carcinoma treatment. Another section of the book focuses on application of cryo-therapy. The book will provide useful information to doctors, oncologists, radiologists, students and researchers.

Gene Therapy of Cancer

• 3rd Edition
• August 28, 2013
• Edmund C. Lattime + 1 more
• English
• Hardback 978-0-12-394295-1

  9 7 8 - 0 - 1 2 - 3 9 4 2 9 5 - 1
• eBook 978-0-12-394632-4

  9 7 8 - 0 - 1 2 - 3 9 4 6 3 2 - 4

Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response.

Lead Compounds from Medicinal Plants for the Treatment of Cancer

• 1st Edition
• October 22, 2012
• Christophe Wiart
• English
• Hardback 978-0-12-398371-8

  9 7 8 - 0 - 1 2 - 3 9 8 3 7 1 - 8
• eBook 978-0-12-398382-4

  9 7 8 - 0 - 1 2 - 3 9 8 3 8 2 - 4

Lead Compounds from Medicinal Plants for the Treatment of Cancer is the first volume in the series, Pharmaceutical Leads from Medicinal Plants. The plant species described in this reference have been carefully selected based on pharmacological evidence and represent today’s most promising sources of natural products for the discovery of anti-cancer drugs. Containing references to primary source material, over a hundred botanical illustrations, a table of chemical structures and much more, this book is an essential starting point for cancer researchers and those involved in anti-cancer drug discovery helping you identify the best novel lead molecules for further anti-cancer drug development.

Current Challenges in Personalized Cancer Medicine

• 1st Edition
• Volume 65
• September 26, 2012
• Keiran Smalley
• English
• eBook 978-0-12-398483-8

  9 7 8 - 0 - 1 2 - 3 9 8 4 8 3 - 8

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.

Novel Anticancer Agents

• 1st Edition
• December 13, 2005
• Alex A. Adjei + 1 more
• English
• Hardback 978-0-12-088561-9

  9 7 8 - 0 - 1 2 - 0 8 8 5 6 1 - 9
• eBook 978-0-08-053775-7

  9 7 8 - 0 - 0 8 - 0 5 3 7 7 5 - 7

Novel Anticancer Agents offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new, relatively non-cytotoxic anticancer agents. At present, there is no book that provides such an integration of basic and clinical studies of novel anticancer agents, covering both drug discovery and translational research extensively.

The SV40 Replicon Model for Analysis of Anticancer Drugs

• 1st Edition
• April 3, 1996
• Robert M. Snapka
• English
• Hardback 978-0-12-653630-0

  9 7 8 - 0 - 1 2 - 6 5 3 6 3 0 - 0
• eBook 978-0-08-055018-3

  9 7 8 - 0 - 0 8 - 0 5 5 0 1 8 - 3

This book provides the most up-to-date review of the simian virus 40 (SV40) minichromosome as a model for the mammalian chromosome in studies of DNA replication. It focuses on disruption of DNA replication by anticancer drugs and DNA-damaging agents. There is a strong emphasis on the unique advantages of SV40 as an experimental system for the analysis of these classes of anticancer drug mechanisms. The new high-resolution gel electrophoresis methods for the analysis of SV40 DNA replication are covered in detail to aid readers in designing and interpreting similar experiments.

Drug Resistance As a Biochemical Target in Cancer Chemotherapy

• 1st Edition
• November 12, 1991
• Makoto Ogawa
• English
• eBook 978-0-323-15388-1

  9 7 8 - 0 - 3 2 3 - 1 5 3 8 8 - 1

Drug Resistance as a Biochemical Target in Cancer Chemotherapy covers the proceedings of the 13th Bristol-Myers Squibb Symposium on Cancer Research, entitled ""Drug Resistance as a Biochemical Target in Cancer Chemotherapy"", hosted by the Japanese Foundation for Cancer Research in Tokyo. This book is divided into four parts encompassing 18 chapters that summarize the results of both preclinical and clinical research on circumvention of drug resistance. The first two parts discuss the genetic aspects of multidrug resistance and the proteins involved in drug resistance. These parts also examine the structure, function, and expression of P-glycoproteins, with an emphasis on the role of these proteins as targets for cancer chemotherapy. The third part describes the methods for detection of P-glycoprotein and its antagonists to counter clinical drug resistance. This topic is followed by a discussion on the interactions among steroid hormones, steroid hormone receptors, antiandrogens, biological-response modifiers, and cytotoxic drugs in human breast cancer. The concluding part explores the clinical applications of chemosensitizers in cancer therapy. This part also considers the alternative clinical approaches against drug failure, including non-crosss-resistant therapies, autologous bone marrow transplantation, dose-intensive therapy, and high-dose chemotherapy. Biomedical scientists and researchers and clinicians will find this book invaluable.